Join Growin Stock Community!

Cel-sci corporationCVM.US Overview

US StockHealthcare
(No presentation for CVM)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CVM AI Insights

CVM Overall Performance

CVM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CVM Recent Performance

-5.99%

Cel-sci corporation

0.05%

Avg of Sector

-0.31%

S&P500

CVM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CVM Key Information

CVM Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CVM Profile

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Price of CVM

CVM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CVM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.46
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11797.42
PB Ratio
2.40
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.46
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
11797.42
PB Ratio
2.40
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CVM's latest earnings report released?

    The most recent financial report for Cel-sci corporation (CVM) covers the period of 2026Q1 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CVM's short-term business performance and financial health. For the latest updates on CVM's earnings releases, visit this page regularly.

  • How much debt does CVM have?

    As of the end of the reporting period, Cel-sci corporation (CVM) had total debt of 9.11M, with a debt ratio of 0.4. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CVM have?

    At the end of the period, Cel-sci corporation (CVM) held Total Cash and Cash Equivalents of 8.6M, accounting for 0.38 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CVM's EPS continuing to grow?

    According to the past four quarterly reports, Cel-sci corporation (CVM)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.68. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CVM?

    Cel-sci corporation (CVM)'s Free Cash Flow (FCF) for the period is -4.02M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 3.61% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.